CVRx gets $84m cash injection for Rheos
This article was originally published in Clinica
CVRx is looking to wrap up clinical studies of its Rheos hypertension control device after securing $84m in its fifth and latest round of financing. New Enterprise Associates and Johnson & Johnson Development Corp were the co-lead investors. The Minneapolis, Minnesota firm will also use the funds to complete product development and build a sales infrastructure in anticipation of a product launch. In addition, the company plans to begin clinical research in the use of Rheos for treating heart failure. The implantable device will be marketed as an alternative treatment option for patients who cannot have their hypertension controlled by drugs. Rheos works by activating the carotid baroreceptors, which play a key role in the body's natural cardiovascular regulation system.